Ste 115, St Louis, MO, 63127, we serve St
Known side effects (class effects similar to other GLP-1 medications) Gastrointestinal issues (very common): Nausea: 38-43% of participants vs 11% placebo Diarrhea: 33-35% vs 13% placebo Vomiting: 20-21% vs 0% placebo Constipation: 22-25% vs 9% placebo Decreased appetite: 18-19% vs 9% placebo These are expected with incretin-based therapies and typically improve over time as your body adjusts
Vomiting after meals, persistent abdominal discomfort, or difficulty eating normal portions may appear
Because of these limitations, the findings should be interpreted as real-world associations rather than definitive causal evidence
Fast and efficient process and the products WORK
As such, the effect of GLP-1RAs on DR should be viewed with caution